医学
肾脏疾病
肾病科
2型糖尿病
糖尿病
内科学
重症监护医学
疾病
内分泌学
作者
Viswanathan Mohan,Awadhesh Kumar Singh,Abdul Hamid Zargar,Alan Almeida,Anil Kumar Bhalla,Jagadish Chander Mohan,Jamshed Dalal,Sahay Manisha,Padhinhare P. Mohanan,Souvik Maitra,Sujoy Ghosh,Tarun Jeloka,Upendra Kaul,Vinay Sakhuja,Mrinal Kanti Das
标识
DOI:10.1016/j.dsx.2022.102661
摘要
The interplay between cardiovascular disease (CVD), chronic kidney disease (CKD) and type 2 diabetes (T2D) is well established. We aim at providing an evidence-based expert opinion regarding the prevention and treatment of both heart failure (HF) and renal complications in people with T2D.ology: The consensus recommendations were developed by subject experts in endocrinology, cardiology, and nephrology. The criteria for consensus were set to statements with ≥80% of agreement among clinicians specialized in endocrinology, cardiology, and nephrology. Key expert opinions were formulated based on scientific evidence and clinical judgment.Assessing the risk factors of CVD or CKD in people with diabetes and taking measures to prevent HF or kidney disease are essential. Known CVD or CKD among people with diabetes confers a very high risk for recurrent CVD. Metformin plus lifestyle modification should be the first-line therapy (unless contraindicated) for the management of T2D. Glucagon-like peptide 1 (GLP-1) agonists can be preferred in people with atherosclerotic cardiovascular disease (ASCVD) or with high-risk indicators, along with sodium-glucose cotransporter-2 inhibitors (SGLT2i), whereas SGLT2i are the first choice in HF and CKD. The GLP-1 agonists can be used in people with CKD if SGLT2i are not tolerated.Current evidence suggests SGLT2i as preferred agents among people with T2D and HF, and for those with T2D and ASCVD. SGLT2i and GLP-1RA also lower CV outcomes in those with diabetes and ASCVD, and the treatment choice should depend on the patient profile.
科研通智能强力驱动
Strongly Powered by AbleSci AI